Top

Published in:

01-08-2018 | IM - CASE RECORD

What is behind a relapse of thrombotic thrombocytopenic purpura?

Authors: Marco Capecchi, Andrea Artoni, Maria Domenica Cappellini, Giovanna Graziadei

Published in: Internal and Emergency Medicine | Issue 5/2018

Excerpt

We present the case of a 64-year-old woman. She was diagnosed with thrombotic thrombocytopenic purpura (TTP) in 2006, at the age of 54 years because of an acute neurological episode of confusion with the presence of schistocytes in the blood smear. Platelet count was up to 100,000/mm³, hemoglobin level was 13 g/dl, with a mean cell volume of 65 fl. She was treated with plasma exchange and steroids with complete resolution of the clinical manifestations, and the follow-up was started. Notably, ADAMTS-13 had not been determined during the acute episode, and at follow-up ADAMTS-13 levels were always within normal limits. …

Inati A, Chabtini L, Mounayar M, Taher A (2009) Current understanding in the management of sickle cell disease. Hemoglobin 33(Suppl 1):S107–S115CrossRefPubMed

Schnog JJ, Kremer Hovinga JA, Krieg S, Akin S, Lämmle B, Brandjes DP, Mac Gillavry MR, Muskiet FD, Duits AJ (2006) ADAMTS13 activity in sickle cell disease. Am J Hematol 81:492–498CrossRefPubMed

Chen J, Hobbs WE, Le J, Lenting PJ, de Groot PG, López JA (2011) The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood 117(13):3680–3683CrossRefPubMedPubMedCentral

Prichard JG, Clark HG, James RE 3rd (1988) Abdominal pain and sicklemia in a patient with sickle cell trait. South Med J 81(10):1312–1314CrossRefPubMed

Geigel EJ, Francis CW (1997) Reversal of multiorgan system dysfunction in sickle cell disease with plasma exchange. Acta Anaesthesiol Scand 41(5):647–650CrossRefPubMed

Bolaños-Meade J, Keung YK, López-Arvizu C, Florendo R, Cobos E (1999) Thrombotic thrombocytopenic purpura in a patient with sickle cell crisis. Ann Hematol 78(12):558–559CrossRefPubMed

Chehal A, Taher A, Shamseddine A (2002) Sicklemia with multi-organ failure syndrome and thrombotic thrombocytopenic purpura. Hemoglobin 26(4):345–351CrossRefPubMed

Shelat SG (2010) Thrombotic thrombocytopenic purpura and sickle cell crisis. Clin Appl Thromb Hemost 16(2):224–227CrossRefPubMed

Chinowsky MS (1994) Thrombotic thrombocytopenic purpura associated with sickle cell-hemoglobin C disease. South Med J 87(11):1168–1171CrossRefPubMed

10.

Lee HE, Marder VJ, Logan LJ, Friedman S, Miller BJ (2003) Life-threatening thrombotic thrombocytopenic purpura (TTP) in a patient with sickle cell-hemoglobin C disease. Ann Hematol 82(11):702–704CrossRefPubMed

11.

Majjiga VS, Tripathy AK, Viswanathan K, Shukla M (2010) Thrombotic thrombocytopenic purpura and multiorgan system failure in a child with sickle cell-hemoglobin C disease. Clin Pediatr (Phila) 49(10):992–996CrossRef

12.

Vlachaki E, Agapidou A, Neokleous N, Adamidou D, Vetsiou E, Boura P (2014) Thrombotic thrombocytopenic purpura or immune thrombocytopenia in a sickle cell/β+-thalassemia patient: a rare and challenging condition. Transfus Apher Sci 51(2):175–177CrossRefPubMed

13.

Gangemi AJ, Pickens PV (2015) Coagulopathy and functional hyposplenism during an episode of thrombotic thrombocytopenic purpura in a HgbS/β(+)-thalassemia patient. Clin Case Rep 3(7):521–526CrossRefPubMedPubMedCentral

Title: What is behind a relapse of thrombotic thrombocytopenic purpura?
Authors: Marco Capecchi
Andrea Artoni
Maria Domenica Cappellini
Giovanna Graziadei
Publication date: 01-08-2018
Publisher: Springer International Publishing
Published in: Internal and Emergency Medicine / Issue 5/2018
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-017-1764-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2018

Daylight saving time, circadian rhythms, and cardiovascular health

Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study

Author Correction: Clinical chameleons: an emergency medicine focused review of carbon monoxide poisoning

Hip fracture unit: beyond orthogeriatrics

A prospective feasibility trial of a novel intravascular catheter system with retractable coiled tip guidewire placed in difficult intravascular access (DIVA) patients in the Emergency Department

Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials